Aromatase Inhibitor (AI)

DRUG3 trials

Sponsors

Eli Lilly and Company, Tvardi Therapeutics, Incorporated, Peking University Cancer Hospital & Institute

Conditions

Advanced Breast CancerBreast CancerEndometrial CancerMetastatic Breast Cancer

Phase 1

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruitingNCT04188548

Eli Lilly and CompanyAdvanced Breast Cancer, Breast Cancer, Endometrial Cancer +1

Start: 2019-12-10End: 2027-12-31Target: 500Updated: 2025-06-04

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

TerminatedNCT05384119

Tvardi Therapeutics, IncorporatedBreast Cancer

Start: 2023-01-09End: 2024-04-25Updated: 2025-02-21

Phase 2

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Not yet recruitingNCT07527806

Peking University Cancer Hospital & InstituteBreast Cancer

Start: 2026-05-01End: 2029-12-31Target: 156Updated: 2026-04-17

Related Papers

Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.

Journal of Clinical Oncology2024-06-012 citations

Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.

Journal of Clinical Oncology2024-06-01

Abstract PS15-09: Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study

Cancer Research2024-05-022 citations

51P ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study

ESMO Open2024-05-01

Abstract PD13-12: PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study

Cancer Research2023-03-0111 citations

A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.

Journal of Clinical Oncology2022-06-0138 citations

Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)

Cancer Research2021-07-0128 citations

A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.

Journal of Clinical Oncology2021-05-2036 citations

Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer

Cancer Research2021-02-159 citations